^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    18h
    Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    19h
    A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease (clinicaltrials.gov)
    P2, N=30, Recruiting, Shandong First Medical University | Phase classification: P1/2 --> P2 | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Phase classification • Trial completion date • Trial primary completion date
    4d
    Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies (clinicaltrials.gov)
    P1, N=42, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC • Leukine (sargramostim)
    4d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Apr 2029 --> Jul 2029
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    4d
    SOUNDTRACK-C1: Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    surovatamig (AZD0486)
    5d
    Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=50 --> 23
    Enrollment closed • Enrollment change
    |
    EZH2 mutation
    |
    Tazverik (tazemetostat) • Lunsumio (mosunetuzumab-axgb)
    6d
    A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=300, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Jun 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • apalutamide • cetrelimab (JNJ-63723283) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • pasritamig (JNJ-8343)
    6d
    A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) (clinicaltrials.gov)
    P1, N=21, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    6d
    Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (clinicaltrials.gov)
    P1, N=82, Recruiting, Amgen | N=34 --> 82
    Enrollment change
    |
    Imdelltra (tarlatamab-dlle)
    6d
    DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=200, Suspended, Amgen | Recruiting --> Suspended
    Trial suspension
    |
    Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle) • YL201
    6d
    Talisman: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events (clinicaltrials.gov)
    P2, N=210, Recruiting, Janssen Research & Development, LLC | N=130 --> 210
    Enrollment change
    |
    Talvey (talquetamab-tgvs)
    6d
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=57, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)